HRDsig positivity was observed in 82% of germline or somatic g/sBRCA1/2 or germline PALB2 (gPALB2) mutated cancers, 13.1% in cancers with other HR-repair (HRR) gene alterations (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, somatic PALB2 (sPALB2), RAD51B, RAD51C, RAD51D and RAD54L), and also in 16.5% of HRR wild-type cancers. This evidence concerns the gene PALB2 and cancer.